DIỄN BIẾN XƠ HOÁ GAN CỦA VIÊM GAN VI RÚT C Ở BỆNH NHÂN ĐỒNG NHIỄM HIV TẠI PHÒNG KHÁM NGOẠI TRÚ HIV BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG

Abstract

The proportion of Vietnamese people co-infectious with HCV and HIV is  high, at about 30-33%; with patients diagnosed to get liver cirrhosis constituting 10-15%. The new DAA medications offer shorter durations of treatment and increased effectiveness, including higher rates of SVR many researches, the progress liver fibrosis has been studied but not much, esptically in co-infection HCV/HIV patients. Due to the fact that there is insufficient data on progressing liver fibrosis and cirrhosis in HCV and HIV co-infection, we decided to conduct the research on patients infected with HIV and HCV, Aiming to achieve goal: access the progress of live fibrosis.  

Material and Method: People in their adulthood got infected with HCV/HIV, tested positive with HCV for longer than six months, already received ARV and DAAs, having SVR and were checked with FibroScan 3 times: Starting DAAs, SRV time and in 2020. These patients were also tested chemically and hematological.

Results and conclusions: The percentage of patients getting liver fibrosis was dropped sharply from 23.6% to 10.9% in study group, follow-up times was 31.1 months (p<0.05). Liver fibrosis mean is reduced 2.2 kPa; The rate of regression liver fibrosis in liver fibrosis (F2-F4) group was 53.8%.